6-Deoxyerythronolide B
Star0
Identification
- Generic Name
- 6-Deoxyerythronolide B
- DrugBank Accession Number
- DB04070
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 386.5228
Monoisotopic: 386.266838948 - Chemical Formula
- C21H38O6
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism U6-deoxyerythronolide B hydroxylase Not Available Saccharopolyspora erythraea (strain NRRL 23338) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The serum concentration of Abemaciclib can be increased when it is combined with 6-Deoxyerythronolide B. Acalabrutinib The serum concentration of Acalabrutinib can be increased when it is combined with 6-Deoxyerythronolide B. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with 6-Deoxyerythronolide B. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with 6-Deoxyerythronolide B. Albendazole The metabolism of Albendazole can be decreased when combined with 6-Deoxyerythronolide B. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Macrolides and analogues
- Sub Class
- Not Available
- Direct Parent
- Macrolides and analogues
- Alternative Parents
- Secondary alcohols / Lactones / Cyclic ketones / Carboxylic acid esters / Polyols / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic heteromonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Hydrocarbon derivative / Ketone / Lactone / Macrolide
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- erythronolide (CHEBI:16089) / Macrolides and lactone polyketides (C03240) / Macrolides and lactone polyketides (LMPK04000002)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- HQZOLNNEQAKEHT-IBBGRPSASA-N
- InChI
- InChI=1S/C21H38O6/c1-8-16-12(4)19(24)13(5)17(22)10(2)9-11(3)18(23)14(6)20(25)15(7)21(26)27-16/h10-16,18-20,23-25H,8-9H2,1-7H3/t10-,11+,12+,13+,14-,15-,16-,18+,19+,20+/m1/s1
- IUPAC Name
- (3R,4S,5R,6S,7S,9R,11R,12S,13R,14R)-14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
- SMILES
- [H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C1=O
References
- Synthesis Reference
Robert McDaniel, "Production of 8,8a-dihydroxy-6-deoxyerythronolide B." U.S. Patent US20010034046, issued October 25, 2001.
US20010034046- General References
- Not Available
- External Links
- PDB Entries
- 1jio / 1oxa / 1z8o / 1z8p / 1z8q / 5mns / 5mnv / 6zi3 / 7q6r / 7q6x … show 1 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.12 mg/mL ALOGPS logP 1.8 ALOGPS logP 2.87 Chemaxon logS -2.5 ALOGPS pKa (Strongest Acidic) 14 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 104.06 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 102.94 m3·mol-1 Chemaxon Polarizability 42.94 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8891 Blood Brain Barrier + 0.8618 Caco-2 permeable - 0.5356 P-glycoprotein substrate Substrate 0.5407 P-glycoprotein inhibitor I Non-inhibitor 0.8554 P-glycoprotein inhibitor II Non-inhibitor 0.7101 Renal organic cation transporter Non-inhibitor 0.9497 CYP450 2C9 substrate Non-substrate 0.8196 CYP450 2D6 substrate Non-substrate 0.8539 CYP450 3A4 substrate Non-substrate 0.5317 CYP450 1A2 substrate Non-inhibitor 0.8867 CYP450 2C9 inhibitor Non-inhibitor 0.8888 CYP450 2D6 inhibitor Non-inhibitor 0.9394 CYP450 2C19 inhibitor Non-inhibitor 0.8459 CYP450 3A4 inhibitor Non-inhibitor 0.5415 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9514 Ames test Non AMES toxic 0.6607 Carcinogenicity Non-carcinogens 0.8856 Biodegradation Not ready biodegradable 0.8668 Rat acute toxicity 2.6539 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9771 hERG inhibition (predictor II) Non-inhibitor 0.9444
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0v4r-1009000000-e12a3871e574e7be5ad8 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0gb9-0009000000-b7bd7cef7d1068b28dee Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0gb9-0009000000-bd5d9f5610c28617360e Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0009000000-27d364195945d23955e2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0udi-0009000000-85f8b8f497f42c573f5e Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0009000000-c53548a24a4b30eb14e3 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014r-0009000000-cb0c4349f5128a55c667 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 202.370514 predictedDarkChem Lite v0.1.0 [M-H]- 178.4115 predictedDeepCCS 1.0 (2019) [M+H]+ 203.621514 predictedDarkChem Lite v0.1.0 [M+H]+ 180.4107 predictedDeepCCS 1.0 (2019) [M+Na]+ 202.618514 predictedDarkChem Lite v0.1.0 [M+Na]+ 186.6477 predictedDeepCCS 1.0 (2019)
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. Details6-deoxyerythronolide B hydroxylase
- Kind
- Protein
- Organism
- Saccharopolyspora erythraea (strain NRRL 23338)
- Pharmacological action
- Unknown
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
- Specific Function
- Catalyzes the NADPH-dependent conversion of 6-deoxyerythronolide B (6-DEB) to erythronolide B (EB) by the insertion of an oxygen at the 6S position of 6-DEB. Requires the participation of a ferredo...
- Gene Name
- eryF
- Uniprot ID
- Q00441
- Uniprot Name
- 6-deoxyerythronolide B hydroxylase
- Molecular Weight
- 45098.685 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Enzymes
1. DetailsCytochrome P450 3A4
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52